Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2016 2
2017 3
2018 1
2019 2
2020 1
2021 6
2022 6
2023 5
2024 6
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Medication "underuse" headache.
Rattanawong W, Rapoport A, Srikiatkhachorn A. Rattanawong W, et al. Cephalalgia. 2024 Apr;44(4):3331024241245658. doi: 10.1177/03331024241245658. Cephalalgia. 2024. PMID: 38613233 Free article. Review.
The underlying cause of inadequate effectiveness of acute medication lies in its inability to halt the propagation of peripheral activation to central sensitization in a timely manner. For oral and injectable preventive migraine medications, insufficient efficacy an …
The underlying cause of inadequate effectiveness of acute medication lies in its inability to halt the propagation of peripheral activation …
Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial.
Wells RE, O'Connell N, Pierce CR, Estave P, Penzien DB, Loder E, Zeidan F, Houle TT. Wells RE, et al. JAMA Intern Med. 2021 Mar 1;181(3):317-328. doi: 10.1001/jamainternmed.2020.7090. JAMA Intern Med. 2021. PMID: 33315046 Free PMC article. Clinical Trial.
IMPORTANCE: Migraine is the second leading cause of disability worldwide. Most patients with migraine discontinue medications due to inefficacy or adverse effects. ...Participants in both groups had fewer migraine days at 12 weeks (MBSR: -1.6 migrai …
IMPORTANCE: Migraine is the second leading cause of disability worldwide. Most patients with migraine discontinue medic …
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P, Dolezil D, Paemeleire K, Stepien A, Stude P, Snellman J, Arkuszewski M, Stites T, Ritter S, Lopez Lopez C, Maca J, Ferraris M, Gil-Gouveia R. Pozo-Rosich P, et al. JAMA Neurol. 2024 May 1;81(5):461-470. doi: 10.1001/jamaneurol.2024.0368. JAMA Neurol. 2024. PMID: 38526461 Free PMC article. Clinical Trial.
IMPORTANCE: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. OBJECTIVE: To compare the efficacy, tolerability, pat …
IMPORTANCE: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability an …
Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review.
Ray R, Virk GS, Regmi N, Shafiq MM, Siddique R, Elfatih Elamin A, Jihad Y, Ali A, Devi H, Essani B. Ray R, et al. Cureus. 2025 Aug 31;17(8):e91347. doi: 10.7759/cureus.91347. eCollection 2025 Aug. Cureus. 2025. PMID: 41035604 Free PMC article. Review.
Migraine is a leading cause of global disability, and conventional preventive therapies often suffer from poor tolerability and low adherence. ...Eleven studies (n > 50,000) met the inclusion criteria. Pooled 12-month adherence was approximately 55% …
Migraine is a leading cause of global disability, and conventional preventive therapies often suffer from poor tolerability an …
Adherence to acute migraine medication: what does it mean, why does it matter?
Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Katić BJ, et al. Headache. 2010 Jan;50(1):117-29. doi: 10.1111/j.1526-4610.2009.01535.x. Epub 2009 Oct 8. Headache. 2010. PMID: 19817884 Review.
Proper use of medications is an important part of successfully managing migraine headache, yet migraineurs frequently switch, discontinue, or delay taking effective prescription therapies such as triptans. Medication persistence in the treatment of chronic-episodic …
Proper use of medications is an important part of successfully managing migraine headache, yet migraineurs frequently switch, disc …
Migraine in Adults: Preventive Pharmacologic Treatments.
Shamliyan TA, Kane RL, Taylor FR. Shamliyan TA, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. Report No.: 13-EHC068-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. Report No.: 13-EHC068-EF. PMID: 23700633 Free Books & Documents. Review.
OBJECTIVES: To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine. ...CONCLUSIONS: For chronic migraine, onabotulinumtoxin A reduced migraine attacks but in …
OBJECTIVES: To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with …
Topiramate in Migraine Prevention: A 2016 Perspective.
Silberstein SD. Silberstein SD. Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Headache. 2017. PMID: 27902848 Review.
Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine preventives that caused weight gain. When guidelines for migraine prevention in episodic migraine were publishe …
Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine …
Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
Varnado OJ, Vu M, Buysman EK, Kim G, Allenback G, Hoyt M, Trenz H, Cao F, Viktrup L. Varnado OJ, et al. Curr Med Res Opin. 2024 Apr;40(4):635-646. doi: 10.1080/03007995.2024.2316864. Epub 2024 Feb 22. Curr Med Res Opin. 2024. PMID: 38334320 Free article.
CONCLUSION: Patients who initiated galcanezumab for migraine prevention had higher treatment adherence and persistence compared with those who initiated SOC medications after 24-month follow-up. Only few patients (3 13%) with migraine, who qualify fo …
CONCLUSION: Patients who initiated galcanezumab for migraine prevention had higher treatment adherence and persistence …
Recent Advances in Pharmacotherapy for Episodic Migraine.
Chan C, Goadsby PJ. Chan C, et al. CNS Drugs. 2019 Nov;33(11):1053-1071. doi: 10.1007/s40263-019-00665-9. CNS Drugs. 2019. PMID: 31556018 Review.
The combination of clear efficacy and excellent tolerability will be welcome in an area where poor adherence to current preventives is common. Rimegepant, ubrogepant and lasmiditan are migraine-specific acute therapies yet to be approved by regulators. ...Bey …
The combination of clear efficacy and excellent tolerability will be welcome in an area where poor adherence to current preventive …
Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics.
Pellesi L, Do TP, Ernst MT, Hallas J, Pottegård A. Pellesi L, et al. J Headache Pain. 2025 Apr 18;26(1):83. doi: 10.1186/s10194-025-02028-w. J Headache Pain. 2025. PMID: 40251473 Free PMC article.
Parameters assessed include demographic and clinical characteristics of users, temporal trends in drug use, treatment adherence, and concomitant use of other migraine therapies. RESULTS: By December 2024, over 140,000 defined daily doses (DDDs) of rimegepant had bee …
Parameters assessed include demographic and clinical characteristics of users, temporal trends in drug use, treatment adherence, and …
45 results